$7.930
+0.030 (+0.38%)收盤時
HBIO 資訊
HBIO 事件
Sees Q2 Adjusted Gross Margin Between 57%-59%
Sees Q2 adjusted gross margin between 57%-59%. Sees Q2 adjusted EBITDA between $1M-$2M. Expects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance.
Reaffirms FY26 Adjusted Gross Margin Outlook Between 58%-60%
Reaffirms FY26 adjusted gross margin outlook between 58%060% and adjusted EBITDA growth between 6%-10%.
Company Reports Q1 Revenue of $20.8M
Reports Q1 revenue $20.8M vs. $21.8M last year. The company noted encouraging adoption rates within its NPI portfolio, specifically the MeshMEA organoid platform and BTX Electroporation systems, which is driving a shift toward a higher-margin product mix. "First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis," said CEO John Duke.
Company Expects Adjusted EBITDA Between $1.0 Million and $2.2 Million
The Company expects: Adjusted EBITDA between $1.0 million and $2.2 million
Mark Frost Appointed CFO on Permanent Basis
Interim CFO Mark Frost Appointed CFO on Permanent Basis
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。